Proceedings of the 2nd Global Health and Innovation in conjunction with 6th ORL Head and Neck Oncology Conference (ORLHN 2021)

Study of SARS-COV 2 Antibody Level Before and After the Third Covid-19 Vaccine Booster on Health Worker in Province of Nusa Tenggara Barat General Hospital

Authors
Rina Lestari1, 2, *, Indana Eva Ajmala1, 2, Prima Belia Fathana1, 2, Yusra Pintaningrum1, 3
1Faculty of Medicine, Mataram University, Mataram, Indonesia
2Pulmonology Department of Province of Nusa Tenggara Barat General Hospital, Mataram, Indonesia
3Cardiology and Vascular Department of Province of Nusa Tenggara Barat General Hospital, Mataram, Indonesia
*Corresponding author. Email: rinalestari@unram.ac.id
Corresponding Author
Rina Lestari
Available Online 21 February 2022.
DOI
10.2991/ahsr.k.220206.069How to use a DOI?
Keywords
COVID-19; Vaccine; Antibody
Abstract

Vaccination is one of the ways that countries around the world to manage the COVID-19. The effectiveness of a vaccine can be assessed from the degree of protective antibodies produced after the vaccination program. The purpose of this study was to determine the levels of SARS-CoV-2 antibodies in the sixth month after two doses of CoronaVac immunization and one month after MRNA-1273 vaccine immunization and to determine the relationship between age, sex, nutritional status, smoking habits and exercise habits on antibody levels in research subjects. Observational research with a cross sectional approach. The sample in this study were health workers who had received COVID-19 immunization who met the inclusion criteria and were taken using a purposive sampling technique. Then the data obtained will be analyzed descriptively using the SPSS program. A total of 29 subjects (51.72% women) participated in this study. The mean age of the research subjects was 35.71 years. The results of the antibody titer examination 6 months after the second dose of CoronaVac immunization (before MRNA-1273 vaccine immunization) showed the lowest antibody titer was 2.17 U/ml and the highest was > 250 U/ml, while the antibody titer 1 month after MRNA-1273 vaccine immunization showed > 250 U/ml in all subjects. The results of the correlation test showed that there were no significant results regarding the relationship between antibody levels 6 months after CoronaVac immunization with age (r= −0.282, p=0.139), gender (r= −0.095, p=0.623), nutritional status (r = 0.007, p = 0.973), smoking habits (r = 0.082, p = 0.672), and exercise habits (r = −0.243, p = 0.204). The levels of antibodies in the sixth month after the second dose of CoronaVac immunization were still detected in the range of 2.17 to > 250 U/ml, while the levels of SARS CoV-2 antibodies in the first month after the MRNA-1273 vaccine immunization all reached the upper limit of the examination. The levels of SARS-CoV-2 antibodies in the sixth month after the second dose of CoronaVac immunization were not significantly related to age, sex, nutritional status, smoking habits and exercise habits.

Copyright
© 2022 The Authors. Published by Atlantis Press International B.V.
Open Access
This is an open access article under the CC BY-NC license.

Download article (PDF)

Volume Title
Proceedings of the 2nd Global Health and Innovation in conjunction with 6th ORL Head and Neck Oncology Conference (ORLHN 2021)
Series
Advances in Health Sciences Research
Publication Date
21 February 2022
ISBN
978-94-6239-540-4
ISSN
2468-5739
DOI
10.2991/ahsr.k.220206.069How to use a DOI?
Copyright
© 2022 The Authors. Published by Atlantis Press International B.V.
Open Access
This is an open access article under the CC BY-NC license.

Cite this article

TY  - CONF
AU  - Rina Lestari
AU  - Indana Eva Ajmala
AU  - Prima Belia Fathana
AU  - Yusra Pintaningrum
PY  - 2022
DA  - 2022/02/21
TI  - Study of SARS-COV 2 Antibody Level Before and After the Third Covid-19 Vaccine Booster on Health Worker in Province of Nusa Tenggara Barat General Hospital
BT  - Proceedings of the 2nd Global Health and Innovation in conjunction with 6th ORL Head and Neck Oncology Conference (ORLHN 2021)
PB  - Atlantis Press
SP  - 370
EP  - 376
SN  - 2468-5739
UR  - https://doi.org/10.2991/ahsr.k.220206.069
DO  - 10.2991/ahsr.k.220206.069
ID  - Lestari2022
ER  -